 BELTSVILLE, Md., July 06, 2021 GLOBE NEWSWIRE -- NextCure, Inc. Nasdaq: NXTC, a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation of a Phase 12 clinical trial for NC762, a humanized B7-H4 monoclonal antibody. 